Monopar Therapeutics Inc (MNPR)

Mar 31, 2025, 8:00 AM EDT - 20 days ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Jan 23, 2025, 1:10 PM EST - 3 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Dec 23, 2024, 2:23 PM EST - 4 months ago

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Dec 20, 2024, 9:00 AM EST - 4 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 5, 2024, 4:21 PM EST - 4 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 3, 2024, 8:00 AM EST - 4 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 25, 2024, 7:53 PM EST - 5 months ago

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Nov 8, 2024, 8:00 AM EST - 5 months ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Oct 30, 2024, 1:42 PM EDT - 6 months ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 9:15 PM EDT - 6 months ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 4:00 PM EDT - 6 months ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 1:29 PM EDT - 6 months ago

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Oct 24, 2024, 1:18 PM EDT - 6 months ago

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

AZN

Oct 22, 2024, 8:00 AM EDT - 6 months ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Oct 15, 2024, 8:00 AM EDT - 6 months ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Sep 12, 2024, 8:00 AM EDT - 7 months ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Aug 27, 2024, 4:05 PM EDT - 8 months ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 21, 2024, 8:00 AM EDT - 8 months ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 14, 2024, 8:00 AM EDT - 8 months ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Aug 9, 2024, 8:00 AM EDT - 9 months ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 9 months ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Jun 25, 2024, 8:00 AM EDT - 10 months ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Jun 11, 2024, 7:30 AM EDT - 11 months ago

Monopar and NorthStar Amend & Extend Collaboration

Jun 10, 2024, 8:00 AM EDT - 11 months ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

May 24, 2024, 8:00 AM EDT - 11 months ago

Monopar Announces CFO Succession

May 9, 2024, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Mar 5, 2024, 7:00 AM EST - 1 year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Feb 27, 2024, 7:00 AM EST - 1 year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 20, 2024, 8:00 AM EST - 1 year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Nov 9, 2023, 7:00 AM EST - 1 year ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Oct 10, 2023, 7:00 AM EDT - 1 year ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Jun 21, 2023, 7:00 AM EDT - 1 year ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 14, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

Mar 28, 2023, 7:00 AM EDT - 2 years ago

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Mar 27, 2023, 5:00 PM EDT - 2 years ago

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Mar 7, 2023, 7:00 AM EST - 2 years ago

Monopar to Present at the 35th Annual Roth Conference

Feb 27, 2023, 7:00 AM EST - 2 years ago

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

Feb 14, 2023, 7:00 AM EST - 2 years ago

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

Jan 26, 2023, 7:00 AM EST - 2 years ago

Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

Jan 18, 2023, 7:00 AM EST - 2 years ago

Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

Dec 12, 2022, 7:00 AM EST - 2 years ago

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

Nov 16, 2022, 7:00 AM EST - 2 years ago

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

Nov 10, 2022, 8:00 AM EST - 2 years ago

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments